Literature DB >> 28039365

Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.

Adah S Zhang1,2, Quinn T Ostrom3,4, Carol Kruchko4, Lisa Rogers3,5, David M Peereboom3,6, Jill S Barnholtz-Sloan3,4.   

Abstract

Background: Complete prevalence proportions illustrate the burden of disease in a population. This study estimates the 2010 complete prevalence of malignant primary brain tumors overall and by Central Brain Tumor Registry of the United States (CBTRUS) histology groups, and compares the brain tumor prevalence estimates to the complete prevalence of other common cancers as determined by the Surveillance, Epidemiology, and End Results Program (SEER) by age at prevalence (2010): children (0-14 y), adolescent and young adult (AYA) (15-39 y), and adult (40+ y).
Methods: Complete prevalence proportions were estimated using a novel regression method extended from the Completeness Index Method, which combines survival and incidence data from multiple sources. In this study, two datasets, CBTRUS and SEER, were used to calculate complete prevalence estimates of interest.
Results: Complete prevalence for malignant primary brain tumors was 47.59/100000 population (22.31, 48.49, and 57.75/100000 for child, AYA, and adult populations). The most prevalent cancers by age were childhood leukemia (36.65/100000), AYA melanoma of the skin (66.21/100000), and adult female breast (1949.00/100000). The most prevalent CBTRUS histologies in children and AYA were pilocytic astrocytoma (6.82/100000, 5.92/100000), and glioblastoma (12.76/100000) in adults. Conclusions: The relative impact of malignant primary brain tumors is higher among children than any other age group; it emerges as the second most prevalent cancer among children. Complete prevalence estimates for primary malignant brain tumors fills a gap in overall cancer knowledge, which provides critical information toward public health and health care planning, including treatment, decision making, funding, and advocacy programs.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  brain tumors; epidemiology; glioblastoma; glioma; prevalence

Mesh:

Year:  2017        PMID: 28039365      PMCID: PMC5464453          DOI: 10.1093/neuonc/now252

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  12 in total

1.  Impaired survival and long-term neurological problems in benign meningioma.

Authors:  Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

2.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

3.  American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter M de Blank; Jonathan L Finlay; James G Gurney; Roberta McKean-Cowdin; Duncan S Stearns; Johannes E Wolff; Max Liu; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

4.  Estimating the completeness of prevalence based on cancer registry data.

Authors:  R Capocaccia; R De Angelis
Journal:  Stat Med       Date:  1997-02-28       Impact factor: 2.373

5.  Estimation and projections of cancer prevalence from cancer registry data.

Authors:  Arduino Verdecchia; Giovanni De Angelis; Riccardo Capocaccia
Journal:  Stat Med       Date:  2002-11-30       Impact factor: 2.373

6.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

7.  Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Authors:  Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-07-14       Impact factor: 4.130

8.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups.

Authors:  F G Davis; V Kupelian; S Freels; B McCarthy; T Surawicz
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

9.  Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.

Authors:  Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  27 in total

1.  Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014.

Authors:  Haley Gittleman; Alexander Boscia; Quinn T Ostrom; Gabrielle Truitt; Yi Fritz; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

Review 2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

3.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

4.  Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Authors:  Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2019-06-17       Impact factor: 4.130

5.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-11-06       Impact factor: 12.300

Review 6.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

7.  Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab.

Authors:  Viveka Nand Yadav; David Altshuler; Padma Kadiyala; Daniel Zamler; Andrea Comba; Henry Appelman; Patrick Dunn; Carl Koschmann; Maria G Castro; Pedro R Löwenstein
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

8.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

9.  BDNF, COMT, and DRD2 polymorphisms and ability to return to work in adult patients with low- and high-grade glioma.

Authors:  David B Altshuler; Lin Wang; Lili Zhao; Zachary Miklja; Joey Linzey; Amanda Brezzell; Sofia Kakaizada; Saritha Krishna; Daniel A Orringer; Emily M Briceño; Nicolette Gabel; Shawn L Hervey-Jumper
Journal:  Neurooncol Pract       Date:  2019-04-10

10.  Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017.

Authors:  Nirav Patil; Michael E Kelly; Debra Nana Yeboa; Robin A Buerki; Gino Cioffi; Sweta Balaji; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.